Bristol-Myers Squibb Co. filed litigation July 7 in federal district court against Merck & Co., alleging Merck’s antibody for treating melanoma infringes a BMS-licensed patent (Bristol-Myers Squibb Co. v. Merck & Co.filed).
BMS said in its complaint filed in the U.S. District Court for the District of Delaware that Merck’s antibody Keytruda (pembrolizumab) infringes claims of U.S. Patent No. 9,073,994 that covers BMS’s antibody OpDivo (nivolumab). BMS, which is based in New York, is the exclusive licensee of the ‘994 patent.
The lawsuit is the latest in a series of actions between BMS and Merck in the U.S. ...
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.